XERS Company Profile and Key Details
Xeris Biopharma Holdings, Inc.
XERS Stock Price Chart
Stock Price Today
Xeris Biopharma Holdings, Inc. (XERS) stock surged +1.10%, trading at $3.68 on NASDAQ, up from the previous close of $3.64. The stock opened at $3.66, fluctuating between $3.64 and $3.73 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Company Information
| Employees | 377 |
| Beta | 1.28 |
| Sales or Revenue | $163.91M |
| 5Y Sales Change% | 4.818% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) stock price is $3.68 in the last trading session. During the trading session, XERS stock reached the peak price of $3.73 while $3.64 was the lowest point it dropped to. The percentage change in XERS stock occurred in the recent session was 1.1% while the dollar amount for the price change in XERS stock was $0.04.
The NASDAQ listed XERS is part of Biotechnology industry that operates in the broader Healthcare sector. Xeris Biopharma Holdings, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Mr. John P. Shannon
Pres & Chief Operating Officer
Mr. Paul R. Edick
Chairman & Chief Executive Officer
Dr. Steven J. Prestrelski M.B.A., MBA, Ph.D.
Co-Founder & Chief Scientific Officer
Ms. Allison Wey
Senior Vice President of Investor Relations & Corporation Communications
Dr. Steven J. Prestrelski MBA, Ph.D.
Co-Founder & Chief Scientific Officer
Mr. Steven M. Pieper
Chief Financial Officer
Dr. Kenneth E. Johnson Pharm. D., Pharm.D.
Senior Vice President of Global Devel. & Medical Affairs
Mr. Kevin McCulloch
Chief Commercial Officer
Ms. Beth P. Hecht J.D.
Chief Legal Officer & Corporation Sec.
XERS's closing price is 115.39% higher than its 52-week low of $1.69 where as its distance from 52-week high of $3.87 is -5.94%.
Number of XERS employees currently stands at 377.
Official Website of XERS is: https://www.xerispharma.com
XERS could be contacted at phone 844 445 5704 and can also be accessed through its website. XERS operates from 180 North LaSalle Street, Chicago, IL 60601, United States.
XERS stock volume for the day was 975.12K shares. The average number of XERS shares traded daily for last 3 months was 1.72M.
The market value of XERS currently stands at $548.62M with its latest stock price at $3.68 and 149.08M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com